Clinical trial
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
NCT00381472 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00381472 |
|---|---|
| Title | Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa |
| Official title | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | Ropinirole |
| Enrollment | 393 |
| Start date | Jun 1, 2003 |
| Completion | Dec 1, 2004 |
| First posted | Sep 27, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: